Global Custom Market Research Reports Provider Company

phone

Global Chronic Lymphocytic Leukemia Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

  • Published Date: 06 Nov 2017
  • Number of Pages: 216
  • Category: Healthcare and Medical
  • Country: Global
Global Chronic Lymphocytic Leukemia Treatment Market:

Global chronic lymphocytic leukemia treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for chronic lymphocytic leukemia treatment is projected to reach US$ XX Mn by 2023.

Chronic lymphocytic leukemia or -cell chronic lymphocytic leukemia, which is the common type of leukemia of the WBC in adults. -cell lymphocytes are a type of white blood cells, which produce in the bone marrow, develop in lymph nodes. These cells produce antibodies which fight against infection. In chronic lymphocytic leukemia, -cells produce in an uncontrolled manner and accumulate in blood and bone marrow, and they crowd out healthy blood cells. Majorly, chronic lymphocytic leukemia occurs in adults, however, sometimes it occurs in the teenagers and children. Chronic lymphocytic leukemia is diagnosed by using complete blood count test, flow cytometry test, gene tests, and bone marrow tests.

The global market for chronic lymphocytic leukemia treatment is expected to grow at a significant CAGR due to increase in the prevalence of chronic lymphocytic leukemia. According to WHO chronic lymphocytic leukemia is more prominent in the developed world such as North America and Europe due to genetic factors. The global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries, which is increased to 123,379 in 2010 and predicted to reach 282,683 new cases for 2020. Increase in aging population, excessive exposure to carcinogenic chemicals, and genetical blood disorders are the major drivers for the growth of chronic lymphocytic leukemia treatment market. Furthermore, growing disease awareness, and rising incidences of comorbidities may accelerates the growth of the market. Increased research and development in oncology sector, introduction of novel therapies, promising pipeline products, and new innovation in drug development helps in the growth of chronic lymphocytic leukemia treatment market. However, the high cost of the treatment for chronic lymphocytic leukemia and stringent regulatory policies might hamper the growth of chronic lymphocytic leukemia treatment market over the forecast period.

Chronic lymphocytic leukemia treatment market has been segmented based on the drug type, route of administration, cancer type, and distribution channel

Based on the drug type, chronic lymphocytic leukemia treatment market has been segmented into the following:

Targeted drug
Purine analogues
Alkylating agents
Corticosteroids
Other drugs
Chemotherapy

Based on the cancer type, chronic lymphocytic leukemia treatment market has been segmented into the following:

B-cell chronic lymphocytic leukemia
T-cell chronic lymphocytic leukemia
Natural killer chronic lymphocytic leukemia

Based on the route of administration, chronic lymphocytic leukemia treatment market has been segmented into the following:

Parenteral
Oral
Others

Based on distribution channel, chronic lymphocytic leukemia treatment market has been segmented into the following:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The global chronic lymphocytic leukaemia treatment market is in developing stage in nature with several international players operating in the chronic lymphocytic leukemia treatment. Conventionally, chemo drugs are dominating the chronic lymphocytic leukemia treatment market. For instance, Rituximab, Imbruvica, and Idelalisib are the chemo drugs used in the treatment of chronic lymphocytic leukemia patients in combination or alone. Efficacy of these drugs in chronic lymphocytic leukemia is potentially replaced chemoimmunotherapy. Co-development and collaboration agreements are some of the key strategies adopted by some market players. For instance, GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of chronic lymphocytic leukemia. Similarly, venetoclax by Roche, in collaboration with AbbVie, received approval from the US FDA for the treatment of chronic lymphocytic leukemia. With an increasing number ofdrugapprovals, the chronic lymphocytic leukemia treatment market is anticipated to post a positive outlook over the forecast period.

Geographically, the chronic lymphocytic leukemia treatment market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. According to American Cancer Society, approximately 15,000 new cases has been observed every year for chronic lymphocytic leukaemia in the country. Chronic lymphocytic leukemia is more prominent in the developed countries like North America and Europe owing to unhealthy lifestyle and genetic factors. Increasing investment in research and development by drug developing firms, improving healthcare infrastructure in India, and China promoting the growth of chronic lymphocytic leukemia treatment market in Asia-Pacific region.

Some of the players in chronic lymphocytic leukemia treatment are Genzyme Corporation (U.S.), Ono pharmaceuticals Co. Ltd. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arno Therapeutics Inc. (U.S.),Infinity Pharmaceuticals (U.S.), Innate Pharma SA (France),AstraZeneca (U.K.), Bellicum Pharmaceuticals Inc. (U.S.),GlaxoSmithKline Plc (U.K.), and Novartis AG (Switzerland) to name a few.

In April 2016, U.S. Food and Drug Administration approved the venetoclax for the treatment of chronic lymphocytic leukemia treatment with 17p chromosome deletion

In 2014, Genentech launched the GA101/RG7159 for the chronic lymphocytic leukemia treatment

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitors overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startups details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Publisher Name : Precision Business Insights
1. Executive summary
2. Global Chronic Lymphocytic Leukemia Treatment Market Introduction
2.1. Global Chronic Lymphocytic Leukemia Treatment Market Taxonomy
2.2. Global Chronic Lymphocytic Leukemia Treatment MarketDefinitions
2.2.1. Drug Type
2.2.2. Cancer Type
3. Global Chronic Lymphocytic Leukemia Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chronic Lymphocytic Leukemia Treatment Market Dynamics Factors Impact Analysis
3.6. Global Chronic Lymphocytic Leukemia Treatment Market Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.7. Global Chronic Lymphocytic Leukemia Treatment Market Recent Product Launches
4. Global Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 2023
4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. Global Chronic Lymphocytic Leukemia Treatment Market, By Drug Type, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Targeted Drugs
5.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Purine Analogues
5.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Alkylating Agents
5.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Corticosteroids
5.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Others
5.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
6. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Cancer Type, 2012 - 2016 and Forecast, 2017 - 2023
6.1. B-cell Chronic Lymphocytic Leukemia
6.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. T-cell Chronic Lymphocytic Leukemia
6.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Natural Killer Chronic Lymphocytic Leukemia
6.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Distribution Channel, 2012 - 2016 and Forecast, 2017 - 2023
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Chronic Lymphocytic Leukemia Treatment Market Forecast, By Region, 2012 - 2016 and Forecast, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 2016 and Forecast, 2017 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Region, 2017 2023
9. North America Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
9.1.1. Drug Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Targeted Drugs
9.1.1.2. Purine Analogues
9.1.1.3. Alkylating Agents
9.1.1.4. Corticosteroids
9.1.1.5. Other Drugs
9.1.2. Cancer Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. B-cell Chronic Lymphocytic Leukemia
9.1.2.2. T-cell Chronic Lymphocytic Leukemia
9.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
9.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Online Pharmacies
9.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 2023
9.1.6. North America Chronic Lymphocytic Leukemia Treatment Market Dynamics Trends
10. Europe Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
10.1.1. Drug Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Targeted Drugs
10.1.1.2. Purine Analogues
10.1.1.3. Alkylating Agents
10.1.1.4. Corticosteroids
10.1.1.5. Other Drugs
10.1.2. Cancer Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. B-cell Chronic Lymphocytic Leukemia
10.1.2.2. T-cell Chronic Lymphocytic Leukemia
10.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
10.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies
10.1.3.3. Online Pharmacies
10.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 2023
10.1.6. Europe Chronic Lymphocytic Leukemia Treatment Market Dynamics Trends
11. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
11.1.1. Drug Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Targeted Drugs
11.1.1.2. Purine Analogues
11.1.1.3. Alkylating Agents
11.1.1.4. Corticosteroids
11.1.1.5. Other Drugs
11.1.2. Cancer Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. B-cell Chronic Lymphocytic Leukemia
11.1.2.2. T-cell Chronic Lymphocytic Leukemia
11.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
11.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Online Pharmacies
11.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan
11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 2023
11.1.6. Asia-Pacific Chronic Lymphocytic Leukemia Treatment Market Dynamics Trends
12. Latin America Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
12.1.1. Drug Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Targeted Drugs
12.1.1.2. Purine Analogues
12.1.1.3. Alkylating Agents
12.1.1.4. Corticosteroids
12.1.1.5. Other Drugs
12.1.2. Cancer Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. B-cell Chronic Lymphocytic Leukemia
12.1.2.2. T-cell Chronic Lymphocytic Leukemia
12.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
12.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Online Pharmacies
12.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 2023
12.1.6. Latin America Chronic Lymphocytic Leukemia Treatment Market Dynamics Trends
13. Middle East & Africa Chronic Lymphocytic Leukemia Treatment Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
13.1.1. Drug Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Targeted Drugs
13.1.1.2. Purine Analogues
13.1.1.3. Alkylating Agents
13.1.1.4. Corticosteroids
13.1.1.5. Other Drugs
13.1.2. Cancer Type Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. B-cell Chronic Lymphocytic Leukemia
13.1.2.2. T-cell Chronic Lymphocytic Leukemia
13.1.2.3. Natural Killer Chronic Lymphocytic Leukemia
13.1.3. Distribution Channel Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Online Pharmacies
13.1.4. Country Analysis (2012 2016) and Forecast (2017 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Chronic Lymphocytic Leukemia Treatment Market- Opportunity Analysis Index - By Drug Type, By Cancer Type, By Distribution Channel, and Country, 2017 2023
13.1.6. MEA Chronic Lymphocytic Leukemia Treatment Market Dynamics Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Genzyme Corporation (U.S.)
14.2.2. Ono pharmaceuticals Co. Ltd. (Japan)
14.2.3. F. Hoffmann-La Roche Ltd. (Switzerland)
14.2.4. AbbVie Inc. (U.S.)
14.2.5. Arno Therapeutics Inc. (U.S.)
14.2.6. Infinity Pharmaceuticals (U.S.)
14.2.7. Innate Pharma SA (France)
14.2.8. AstraZeneca (U.K.)
14.2.9. Bellicum Pharmaceuticals Inc. (U.S.)
14.2.10. GlaxoSmithKline Plc (U.K.)
14.2.11. Novartis AG (Switzerland)
15. Research Methodology
16. Key Assumptions and Acronyms

In this report, the global Zipper market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at

View Report

In this report, the global Work Apparel market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

View Report

In this report, the global Womens Handbags market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports